SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is experiencing explosive momentum, driven by a massive short squeeze following a new strategic deal, with many comparing its parabolic ascent to legendary past runners. The community is buzzing with excitement and disbelief over the rapid gains, focusing on its low float and high short interest as key factors fueling the dramatic price action.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community emphasizes a 'Bongterm' vision, prioritizing cultural sovereignty and consistent, patient growth on the Solana blockchain. Discussions highlight its identity as a 'plant-paced project' focused on education and community values, often proclaiming it as 'like Bitcoin but way higher' due to its enduring connection to evolving cannabis culture and broader societal shifts.

Trump For President

TRUMP CRYPTO is actively trending amid intense community discussion, largely driven by political developments surrounding Venezuela and broader speculation about global influence. While supporters link the coin's potential for significant gains to the former president's ongoing political actions, many others express strong skepticism, highlighting the asset's volatility and lack of intrinsic value.

AXS is the governance token for the Axie Infinity game. Token holders will be able to shape and vote for the direction of the game universe. This is unlike traditional games where all decisions are made by the game developers. AXS holders will be able to stake their tokens to earn more AXS and even vote for governance proposals.

Axie Infinity

Axie Infinity (AXS) is trending amid renewed interest in gaming tokens, with community discussions buzzing around recent developments and potential catalysts. Speculation about integrations like Apple Vision Pro and the launch of its AI agent, JAIHOZ, are driving conversations. Many anticipate Axie Infinity could be entering a significant accumulation phase, drawing comparisons to its historical market performance as the GameFi sector gains momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following the completion of its Astria Therapeutics acquisition, which significantly expands its hereditary angioedema (HAE) pipeline with the late-stage drug navenibart. The community is actively discussing the strategic implications, including favorable new financing terms and a recent ORLADEYO price increase, while debating preliminary guidance that some view as conservative sandbagging by new leadership. Amidst strong revenue growth and expectations for profitability, many express frustration over the stock's perceived undervaluation and ongoing market dynamics.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

Cel-Sci (CVM) is trending as the community hotly debates the imminent potential approval of its Multikine treatment by the Saudi Food and Drug Authority (SFDA), a decision keenly watched by investors. Enthusiasts cite a strategic partnership and encouraging trial subgroup data as positive indicators, while critics express concern over past development timelines, ongoing equity dilution, and questions about the product's broader regulatory path, particularly in the US.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is garnering significant attention as its strategic bank acquisition positions it to transition into a regulated financial institution, a move the community hails as a game-changer for its integrated payment infrastructure. Enthusiastic discussions highlight Keeta's high transaction speed and built-in compliance, projecting its potential to redefine global finance through native fiat rails and real-world asset tokenization. The strong backing from a former Google CEO further fuels optimism about its long-term impact on compliant cross-chain payments.

Alchemy Pay

Alchemy Pay (ACH) is generating buzz due to its ongoing expansion of fiat-to-crypto payment gateways, securing multiple U.S. Money Transmitter Licenses, and numerous partnerships enhancing its global on/off-ramp capabilities. The community is particularly focused on its transition to a Layer-1/Layer-2 blockchain with a stablecoin-focused whitepaper, viewing these architectural upgrades and increased token utility as key drivers for potential appreciation, despite some market skepticism.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is a hot topic among traders following a new manufacturing partnership aimed at bolstering production and margins, coupled with a significant private placement. The community is actively discussing the potential for a short squeeze, citing a low float and high cost to borrow, while also debating the impact of future share dilution. Anticipation for pending FDA approval for its non-invasive drug testing technology is a key factor in long-term sentiment.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is actively discussed as a recent partnership with OpenAI to embed AI agents into its enterprise workflows generates buzz amidst a broader software sector sell-off. While many in the community view the stock as deeply oversold and a compelling long-term opportunity given strong fundamentals and management's optimistic outlook, others express frustration over its persistent decline, questioning the immediate impact of AI initiatives against market headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
